Clinical trial
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2…
NCT01095666 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT01095666 |
|---|---|
| Title | A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | AstraZeneca, Bristol-Myers Squibb |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Dapagliflozin, Metformin, Dapagliflozin Placebo, Pioglitazone |
| Enrollment | 1,484 |
| Start date | Jun 1, 2010 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Mar 30, 2010 |
| Last update posted | Sep 11, 2017 |
| Countries | China, India, South Korea |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: